video corpo

OptiLIGHT
1 / 6Pages

Catalog excerpts

OptiLIGHT - 1

RELEASE NEW DRAWING Update label – wording fix Mor Bisk Vadim Andreyev 1. Material: Polyester. 2. Adhesive back: 3M 7871 - UL MH16411 or equivalent. 3. Background colors: Yellow: C=0; M=0; Y=100; K=0. 4. Graphics symbols color: Black over background. 5. Text color: Black over background. 6. Text font: Arial.

Open the catalog to page 1
OptiLIGHT - 2

E EVATING DRY EYE MANAGEMENT LUMENIS PUTS THE POWER TO MANAGE DRY EYE DISEASE IN THE PALM OF YOUR HAND impacting vision and quality of life as well as the outcomes of ophthalmic surgeries. 1 Introducing the first and only light Therapy, FDA-approved for management of dry eye disease due to meibomian gland dysfunction (MGD), the leading cause of dry eye disease.2 With clinically proven, patented technologies, the power for treating dry eye disease is in the palm of your hand. Get the safe, precise, therapy patients need to manage dry eye disease with OptiLIGHT.

Open the catalog to page 2
OptiLIGHT - 3

which the authorized recipient agrees to protect & not to disclose. ELEVATE YOUR PRACTICE ELEVATE PATIENT CARE With OptiLIGHT in your practice, your patients can count on you for a medical solution to a frustrating condition. OptiLIGHT is easy to use, with minimal training and set-up. OptiLIGHT also helps expand your practice with a new line of treatment and upgrade to aesthetics treatments. Lumenis is here to help, with clinical training and marketing support to enhance your growth. Each treatment takes about 15 minutes, so you can easily integrate OptiLIGHT into the workflow. Patients...

Open the catalog to page 3
OptiLIGHT - 4

BREAK THE DRY EYE VICIOUS CYC E OF INF AMMATION With every pulse of light, this first-of-its-kind light-based treatment works to control the inflammatory process and to improve signs of dry eye disease due to MGD. Peer-reviewed clinical studies show that Lumenis IPL with OPT addresses the dry eye vicious cycle of inflammation: * Decreases the level of pro-inflammatory mediators to inhibit inflammation 3 Restores meibomian glands functionality 4,8 Alleviates the abnormal blood vessels that perpetuate inflammation 5,6 Increases tear breakup time 9 Decreases the population of Demodex mites,...

Open the catalog to page 4
OptiLIGHT - 5

EVERY E EMENT DESIGNED FOR A PRECISE AND COMFORTAB E DRY EYE PROCEDURE PATENTED OPT® HANDPIECE Treat the delicate facial contours of each individual patient. The patented OPT® handpiece is easily customized to fit every curve and outline. ERGONOMIC IPL HANDPIECE Treat wider areas safely and comfortably using the IPL handpiece with patented SapphireCoolTM PERSONALIZED EXPERIENCE FOR SAFETY AND COMFORT Experience optimal energy control at the tip of your OptiLIGHT, for targeted,precise, hygienic and controlled treatment, especially for delicate areas. PROVEN SETTINGS AND PROTOCOLS Utilize...

Open the catalog to page 5
OptiLIGHT - 6

TECHNICA PARAMETERS System Specifications Dimensions [without ResurFX] Dimensions [with ResurFX] Weight [without ResurFX] OptiLIGHT Spectrum ExpertFilters* Lightguides Maximal Fluence** Pulse Duration** Pulse Delay** Weight [with ResurFX] Electrical requirements Pulse Characteristic Multiple Sequential Pulsing Repetition Rate Spot Size single phase, dedicated line Indication for Use: In EU: Evaporative Dry Eye Disease (DED), also known as dry eye syndrome or lipid tear deficiency, due to Meibomian Gland Dysfunction (MGD). In US: Improvement of signs of Dry Eye Disease (DED) due to Meibomian...

Open the catalog to page 6

All Lumenis catalogs and technical brochures

  1. AcuPulse

    5 Pages

  2. NuEra Tight

    8 Pages

  3. Stellar M22

    8 Pages

Archived catalogs

  1. ResurFX™

    4 Pages

  2. UltraPulse®

    6 Pages